RecruitingNot ApplicableNCT06037902
CPAP for Esophageal Cancer With Radiotherapy
Use of CPAP (Continuous Positive Airway Pressure) for Simulating Esophageal Cancer Patients Prior to Radiotherapy
Sponsor
Sheba Medical Center
Enrollment
44 participants
Start Date
Aug 21, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to test the use of CPAP in patients with esophgaeal cancer undergoing radiotherapy. The main questions it aims to answer are: * does use of CPAP decrease exposure of normal lung to radiation? * does use of CPAP decrease exposure of normal heart to radiation? Participants will undergo simulation twice: * with CPAP * without CPAP
Eligibility
Min Age: 18 Years
Inclusion Criteria8
- Diagnosis of cancer, with a tumor (primary or secondary) in the esophagus including tumors in the esophagus-stomach junction.
- Age ≥ 18
- Planned RT treatment
- The level of functioning ≥ 60 on the Karnofsky scale
- Life expectancy ≥ two months
- All patients must understand the informed consent form document and sign it of their own free will before any test/procedure related to the study is performed.
- Able to undergo simulation and radiation with CPAP
- Candidate patients can be recruited to receive definitive, palliative or pre-operative radiation, with or without chemotherapy.
Exclusion Criteria5
- Pregnancy or breastfeeding
- Significant comorbidity at the starting point that would prevent the use of CPAP
- Hospitalized in an institution by virtue of an administrative order or a court order.
- Special population
- A history of a psychiatric problem that may impair the patient's ability to understand the research requirements or respond to them, or to give his consent
Interventions
DEVICECPAP
patients undergo simulation twice, with and without CPAP
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06037902
Related Trials
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT0721770410 locations
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT0644597243 locations
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT0646994443 locations